Efficacy and Safety of Xinyue Capsule for Coronary Artery Disease after Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Table 1
Characteristics of included XYC RCTs for CAD after PCI.
T/C, treatment/control; CWMT, conventional western medicine treatment; XYC (SFDA registry number: Z20030073), two capsules orally, three times daily; Fufang Chuanxiong capsule (SFDA registry number: 0802205), two capsules orally, three times daily; ① primary cardiovascular events; ② heart function; ③ NT-pro-BNP; ④ quality of life; ⑤ adverse reaction.